Innovative stem cell technologies have potential to treat Alzheimer’s disease.
http://www.thegamesshed.com/4764-writing-philosophy-papers/ blackmarket viagra prostate cancer viagra treatment go to site go site viagra in the waters kareoke nose hair cialis follow link source get link http://essexlibrary.org/essay-content-5840/ prescription s viagra portarico viagra how can i get cialis in australia https://erc.cals.wisc.edu/wp-content/blogs.dir/25/store.php?usp=cialis-generika-paypal follow url buy custom essay Viagra 100 Mg Best Price follow site top rated essay writing websites alice walker essay novel writer helper term paper help follow essay cover letter free essays biofuel follow site viagra generic wal-mart Today, there is no cure for Alzheimer’s disease and dementia. In 2015, dementia affected more than 46.8 million people worldwide, according to Alzheimer’s Disease International, and an estimated 60-80 percent of those patients have Alzheimer’s disease. The number of dementia cases is expected to grow to 74.7 million in 2030 and to reach 131.5 million in 2050. Stemedica International is the only company to leverage three patented, stem cell technologies (itMSCs, itNSCs and related growth factors) for therapies that may be able to address the global, unmet need for treatments of degenerative conditions, including Alzheimer’s disease and vascular dementia. Stemedica International is also exploring opportunities to prevent the condition, based on promising pre-clinical data.
Stemedica International is using cGMP allogeneic stem cells derived from healthy adult volunteers in clinical trials. Manufactured in a licensed facility under cGMP conditions, the company has successfully completed the safety phase of a clinical trial.